(Q53911458)

22 May 2018

title

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group. (English)

1 reference

22 May 2018

1 reference

Simmons ST

1

1 reference

22 May 2018

Samuelson TW

series ordinal

2

1 reference

22 May 2018

publication date

1 April 2000

1 reference

22 May 2018

published in

Clinical Therapeutics

1 reference

22 May 2018

volume

22

1 reference

22 May 2018

issue

4

1 reference

22 May 2018

page(s)

388-399

1 reference

22 May 2018

Efficacy of combining timolol with other antiglaucoma medications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Shortterm “escape” and longterm “drift.”. The dissipation effects of the beta adrenergic blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Perspectives in the medical treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

Latanoprost for uncontrolled glaucoma in a compassionate case protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989008-6

7 January 2021

10.1016/S0149-2918(00)89008-6

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

10823361

1 reference

22 May 2018